IGF2BP3 and neoplasm: By analyzing the expression of eight signatures in different tumor stages using R software, it was found that the expression of IGF2BP3, PLK1, LINC00200, NCAPG, CENPF, and miR_217 in the early stage of the tumor were lower than that in the late stage, while GAS6_AS1 and LRRC4 were opposite, and the result was consistent with the above survival analysis.